Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
Explore this paper's citation graph
Summary
Fusion gene structure and expression results in loss of wild‐type alleles and recruitment of additional molecules by the fusion partner, which triggers TK activation.
- Type
- review
- Published
- 2012-01-27
- Cited by
- 94
- References
- 117
- Access
- Open access
- OpenAlex
- https://openalex.org/W2000223052
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:15904286
Keywords
Cancer research, Tyrosine kinase, Biology, Receptor tyrosine kinase, Crizotinib
References
- Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cγ at the centrosome
- TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins.
- Signaling networks associated with BCR-ABL-dependent transformation.
- Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).
- Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras
- DNA Breaks at Fragile Sites Generate Oncogenic RET/PTC Rearrangements in Human Thyroid Cells
- Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
- Structure of the Bcr-Abl oncoprotein oligomerization domain
- Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway.
- TICdb: a collection of gene-mapped translocation breakpoints in cancer
- Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data
- The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells
- Transforming Properties of the Huntingtin Interacting Protein 1/ Platelet-derived Growth Factor β Receptor Fusion Protein*
- Anaplastic lymphoma kinase: signalling in development and disease
- The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation.
- TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins.
- Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.
- Targeting myeloproliferative neoplasms with JAK inhibitors
- The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif.
- A common phosphotyrosine signature for the Bcr-Abl kinase.
Cited by
- PDGF receptor signaling networks in normal and cancer cells.
- Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma
- [Inflammatory myofibroblastic tumor of common bile duct].
- Detecting and characterizing fusions and tandem duplications in acute myeloid leukemia transcriptome assemblies using Barnacle
- Conditional in vivo expression of the fusion kinase ITK-SYK
- Effects of siRNA-squalene nanoparticles on RET/PTCs junction oncogenes in papillary thyroid carcinoma : from molecular and cellular studies to preclinical investigations
- Genetic Predictors of Clinical Outcomes in Non-Small Cell Lung Cancer Patients
- Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma
- Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis.
- Kinase dysfunction and kinase inhibitors.
- Direct electrochemical oxidation of Abelson tyrosine-protein kinase 1 and evaluation of its interaction with synthetic substrate, ATP and inhibitors
- Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia
- ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB
- Use of signaling pathways as therapeutic targets for blood cancer
- Enhanced expression and phosphorylation of the MET oncoprotein by glioma‐specific PTPRZ1–MET fusions
- Allostery in disease and in drug discovery.
- Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.
- Mouse Model for ROS1-Rearranged Lung Cancer
- Targeting cancer with kinase inhibitors.
- The promoter methylation of the Syk gene in nasopharyngeal carcinoma cell lines.
Related papers
- Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma
- ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
- Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer
- ALK-driven tumors and targeted therapy: focus on crizotinib
- How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature
- Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
- Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.
- Anaplastic lymphoma tyrosine kinase oncogene in human cancer: gene aberrations, methods of detection and therapeutic potential
- Review of the use of ceritinib, a newly approved anaplastic lymphoma kinase (ALK) inhibitor, in crizotinib-resistant anaplastic lymphoma kinase-rearranged non-small cell lung cancer